Abstract:The present study is focused on expression of a target fusion protein which can be used in ovarian cancer target therapy. It aimed to construct human urokinase-type plasminogen activator (uPA)(1-43)-melittin eukaryotic expression vector to express recombinant human uPA(1-43)-melittin (rhuPA(1-43)-melittin) in P. pastoris and to detect its anticancer effects on ovarian cancer cells. The DNA sequences that encode uPA1-43 amino acids and melittin were synthesized according to its native amino acid sequences and consequently inserted into pPICZαC vector. Then uPA1-43-melittin -pPICZαC was transformed into P. pastoris X-33, and rhuPA(1-43)-melittin was expressed by methonal inducing. The bioactivities of recombinant fusion protein were detected with inhibition effects on growth of ovarian cancer cells, cell cycle detection and TUNEL assay. The results of DNA sequence analysis of the recombinant vector uPA(1-43)-melittin -pPICZαC demonstrated that the DNA encoding human uPA 1-43 amino acids and 1-26 amino acids of melittin was correctly inserted into the pPICZαC vector. After being induced by methonal, fusion protein with molecular weight 7.6 kDa was observed on the basis of SDS-PAGE and western blot analysis. The recombinant protein was able to suppress growth of SKOV3, induce cell cycle arrest and apoptosis of SKOV3 cells. The fusion protein does not have any obvious toxicity on normal tissues. RhuPA(1-43)-melittin was successfully expressed in P. pastoris. Taking uPA(1-43) amino acids specifically binding to uPAR as targeted part of fusion protein, and making use of antitumor activity of melittin, the recombinant fusion protein it was able to inhibit growth of ovarian tumors and to be applied for effective targeted treatment.

An Upa Cleavable Conjugate Of A Recombinant Alpha V Beta 3 Targeting Toxin And Its Bioactivity

An uPA cleavable conjugate of a recombinant αvβ3 targeting toxin and its bioactivity

Expression and Functional Characterization of a Recombinant Targeted Toxin with an Upa Cleavable Linker in Pichia Pastoris.

The anti-cancer potency and mechanism of a novel tumor-activated fused toxin, DLM.

T351 Protein, a Novel Tumor Associated Antigen and Potential Target for Immunotherapy

Acid-Activated Melittin for Targeted and Safe Antitumor Therapy.

Genetically engineered nano-melittin vesicles for multimodal synergetic cancer therapy

Preparation and Functional Characterization of Human Vascular Endothelial Growth Factor-Melittin Fusion Protein with Analysis of the Antitumor Activity in Vitro and in Vivo.

Construction and characterization of an anti-asialoglycoprotein receptor single-chain variable-fragment-targeted melittin.

Expression and Anticancer Activity Analysis of Recombinant Human Upa1–43-Melittin

Expression,purification and Preliminary Identification of a Novel Immunotoxin Against Hepatocarcinoma

Melittin-encapsulating Peptide Hydrogels for Enhanced Delivery of Impermeable Anticancer Peptides.

A Biomimetic Nanoparticle-Enabled Toxoid Vaccine Against Melittin

Hybrid Melittin Cytolytic Peptide-Driven Ultrasmall Lipid Nanoparticles Block Melanoma Growth <i>in Vivo</i>

A Novel Tumor-Activated ALA Fusion Protein for Specific Inhibition on the Growth and Invasion of Breast Cancer Cells MDA-MB-231

Melanocyte-Stimulating Hormone-Related Diphtheria Toxin Targets to Lung Adenocarcinoma

Melittin-A Natural Peptide from Bee Venom Which Induces Apoptosis in Human Leukaemia Cells

Application of bee venom and its main constituent melittin for cancer treatment

Enhanced Binding to and Killing of Hepatocellular Carcinoma Cells in Vitro by Melittin when Linked with a Novel Targeting Peptide Screened from Phage Display

Vascular Basement Membrane-Derived Multifunctional Peptide, A Novel Inhibitor of Angiogenesis and Tumor Growth

Hybrid melittin cytolytic Peptide-driven ultrasmall lipid nanoparticles block melanoma growth in vivo.